Coeptis Therapeutics Has Expanded Its Exclusive License Agreement With The University Of Pittsburgh To Include The SNAP-CAR Technology Platform In Natural Killer Cells
Portfolio Pulse from Benzinga Newsdesk
Coeptis Therapeutics has expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer cells. This builds upon the original agreement for SNAP-CAR T-Cell, a platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including HER2-expressing cancer.
October 11, 2023 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coeptis Therapeutics' expanded agreement with the University of Pittsburgh could potentially enhance its product portfolio and address a wider range of cancers.
The expanded agreement allows Coeptis Therapeutics to include the SNAP-CAR technology in natural killer cells, which could potentially enhance its product portfolio and address a wider range of cancers. This could potentially lead to increased revenues and a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100